Abstract
The acute effect of glibenclamide, a hypoglycemic sulfonylurea, upon transglutaminase activity was investigated in 6 type II diabetic patients by perfusing 1 mg glibenclamide during 1 h. Blood samples were drawn 0, 10, 20, 30, 60 min during and 30 and 60 min after perfusion to determine insulin, glucose and transglutaminase activity. No significant modifications in plasma insulin, plasma glucose and transglutaminase activity in red cells was induced by glibenclamide perfusion. Nevertheless, glibenclamide induced a significant decrease (p < 0.005) in transglutaminase activity after 20 min of perfusion (629.83 ± 53.08 and 521.18 ± 43.92, mean ± SE, at 0 and 20 min). No correlation was observed between glucose or insulin plasma levels and transglutaminase activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Pfeifer M.A., Halter J.B., Judzewitsch T.G., Beard J.C., Best J.D., Ward W.K., Porte D. Acute and chronic effects of sulfonylurea drugs on pancreatic islet function in man. Diabetes Care 7(Suppl. 1): 25, 1984.
Kolterman D.G., Olefsky J.M. The impact of sulfonylurea treatment upon the mechanisms responsible for the insulin resistance in type II diabetes. Diabetes Care 7(Suppl. 1): 81, 1984.
Gomis R., Mathias P.C., Lebrun P., Malaisse-Lagae F., Sener A., Malaisse W.J. Inhibition of transglutaminase by hypoglycaemic sulfonylureas in pancreatic islets and its possible relevence to insulin release. Res. Commun. Chem. Pathol. Pharmacol. 46: 331, 1984.
Gomis R., Casanovas A., Casamitjana R., Sarto A., Arroyo J., Belmonte D., Rivera F., Vilardell E. The effect of hypoglycaemic sulfonylureas on human red cell transglutaminase levels. Diabetes Res. Clin. Practice, (in press.)
Gomis R., Sener A., Malaisse-Lagae F., Malaisse W.J. Transglutaminase activity in pancreatic islets. Biochim. Biophys. Acta 760: 384, 1983.
Folk J.E. Transglutaminases. Ann. Rev. Biochem. 49: 517, 1980.
Sener A., Dunlop M.E., Gomis R., Mathias P.C.E., Malais-se-Lagae F., Malaisse W.J. Role of transglutaminase in insulin release. Study with glycine and sarcosine methylester. Endocrinology 117: 237, 1985.
Paonesa G., Metafora S., Tajana G., Abrescia P., De Santes A., Gentile V., Porta R. Transglutaminase mediated modifications of the rat sperm surface in vitro. Science 226: 852, 1984.
Levitzki A., Willingham M., Pastan I. Evidence for participation of transglutaminase in receptor mediated endocytosis. Proc. Natl. Acad. Sci. USA 77: 2706, 1980.
Stanley L., Schrier J.L., Jung I. The role of transglutaminase in human erytrocyte endocytosis. Biochem. Biophys. Res. Commun. 99: 58, 1981.
Davies P.J.A., Davies D.R., Levitzki A., Maxfield F.R., Milhaud P., Willingham M.C., Pastan I.H. Transglutaminase is essential in receptor-mediated endocytosis of 2-macroglobulin and polypeptide hormones. Nature 283: 162, 1980.
Novak S.M., McCaleb M.L., Lockwood D.H. Extrapancreatic action of sulfonylureas; hypoglicaemic effects are not dependent on altered insulin binding or inhibition of transglutaminase. Metabolism 32: 398, 1983.
Morgan C.R., Lazarow A. Immunoassay of insulin: two antibodies system. Diabetes 21(Suppl. 2): 661, 1972.
Feldman J.M., Lebovitz H.E. Endocrine and metabolic effects of glibenclamide. Diabetes 20: 745, 1971.
Prince M.J., Olefsky J.M. Direct in vitro effect of a sulfonylurea to increase human fibroblast insulin receptors. J. Clin. Invest. 66: 608, 1980.
Gambhir K.K., Archer J.A., Bradley C.J. Characteristics of human erythrocyte insulin receptors. Diabetes 27: 701, 1987.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Coves, M.J., Gomis, R., Ribes, J.L.L. et al. Acute effect of glibenclamide upon red cell transglutaminase activity in diabetic patients. J Endocrinol Invest 10, 565–568 (1987). https://doi.org/10.1007/BF03346995
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03346995